Shares of women’s health drug developer TherapeuticsMD Inc. soared in late trading Monday after the company said its trial of a hormonal treatment to reduce vaginal pain during intercourse was successful.

In a final-stage trial of 764 post-menopausal woman, all three dosage levels of TherapeuticsMD’s estradiol treatment helped reduce pain during intercourse for post-menopausal patients with vulvar and vaginal atrophy, when compared to a placebo, the company said in a statement. Estradiol is a reproductive hormone that helps with the growth and maintenance of reproductive tissues. It also plays a key role during puberty.

The shares climbed as much as 65 percent, and were up 45 percent to $9.44 at 4:52 p.m. in New York after the market closed.

The softgel capsule, called TX-004HR, is Boca Raton, Florida-based TherapeuticsMD’s most advanced experimental product. It’s inserted into the vagina without using an applicator.

About 32 million women in the U.S. suffer from symptoms of vulvar and vaginal atrophy, a thinning and drying of the tissue that can lead to painful symptoms, though few are getting treatment, according to the drugmaker.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE